C12N 2501/724
Glycosyltransferases
Official title: Glycosyltransferases (EC 2.4.)
C12N2501/724 (Glycosyltransferases) appears on 46 US grants and 111 published applications in this corpus.
Search patents in C12N- Granted patents
- 46
- Published applications
- 111
- Assignees
- 56
- Inventors
- 120
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 4 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 3 | 9 |
| 2017 | 1 | 14 |
| 2018 | 3 | 13 |
| 2019 | 11 | 16 |
| 2020 | 9 | 7 |
| 2021 | 4 | 11 |
| 2022 | 1 | 5 |
| 2023 | 0 | 6 |
| 2024 | 6 | 7 |
| 2025 | 5 | 9 |
| 2026 | 1 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Reprogramming methods and cell culture platforms5 May 2026US 12,618,049 B2Fate Therapeutics, Inc.
- Methods and products for improving sperm quality30 Dec 2025US 12,508,255 B2The University of Adelaide
- Selective oxidation of 5-methylcytosine by tet-family proteins11 Nov 2025US 12,467,082 B2Children's Medical Center Corporation
- Selective oxidation of 5-methylcytosine by TET-family proteins24 Jun 2025US 12,338,489 B2Children's Medical Center Corporation
- Selective oxidation of 5-methylcytosine by TET-family proteins17 Jun 2025US 12,331,346 B2Children's Medical Center Corporation
- Reprogramming methods and cell culture platforms1 Oct 2026US 2026/0297537 A1Fate Therapeutics, Inc.
- Combination inhibitors for treating fibrosis4 Jun 2026US 2026/0152533 A1Memorial Hospital for Cancer and Allied Diseases
- Compositions and methods for production of exofucosylated cells for clinical applications23 Apr 2026US 2026/0109950 A1
- Methods and products for improving sperm quality26 Mar 2026US 2026/0083719 A1The University of Adelaide
- Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof11 Dec 2025US 2025/0375523 A1Targazyme, Inc.
Most cited
By later US patents
- Selective oxidation of 5-methylcytosine by TET-family proteins46US 9,447,452 B2Children's Medical Center Corporation · 2016
- Selective oxidation of 5-methylcytosine by TET-family proteins41US 9,115,386 B2Children's Medical Center Corporation · 2015
- Detection of 5-hydroxymethylcytosine by glycosylation33US 9,816,986 B2Children's Medical Center Corporation · 2017
- Selective oxidation of 5-methylcytosine by TET-family proteins26US 10,031,131 B2Children's Medical Center Corporation · 2018
- Labeling hydroxymethylated residues26US 10,337,053 B2Children's Medical Center Corporation · 2019